They specialize in Infectious Disease Medicine, has 37 years of experience, and is board certified in Internal. He graduated with honors from Midwestern University, Chicago College Of Osteopathic Med in 1972. Infectious disease specialists deal with a broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia. Dr. Gulick has three offices in Michigan where he specializes in Infectious Disease Medicine and Hematology / Oncology. Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients, Nathalie C. Casau, Marshall J. Glesby, Simon Paul, Roy M. Gulick, Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine, Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW, Antiretroviral Therapy: When and What to Start-- An American Perspective, A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients, Van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia A, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Banhegyi D, Johnson V, van der Valk M, Reiss P, van Weert L, van Leth F, Sommadossi J-P, Lange J. HIV treatment strategies: planning for the long term. Dr. Dr. Gulick currently conducts clinical research, sees patients with infectious diseases, and teaches medicine. Roy M. Gulick, Margo Heath-Chiozzi, Clyde S. Crumpacker, Recombinant, truncated CD4 molecule (rT4) binds IgG, Lederman S, Yellin MJ, Cleary AM, Gulick R, Chess L, Varicella-zoster virus disease in patients with human immunodeficiency virus infection, Gulick RM, Heath-Chiozzi M, Crumpacker CS. Heather J. Ribaudo, Daniel R. Kuritzkes, Bruce R. Schackman, Edward P. Acosta, Cecilia M. Shikuma, Roy M. Gulick, A Randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086, Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW, Design issues in initial HIV-treatment trials focus on ACTG 5095, Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM, Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti, Patrice Severe, Paul Leger, Macarthur Charles, Francine Noel, Gerry Bonhomme, Gyrlande Bois, Erik George, Stefan Kenel-Pierre, Peter F. Wright, Roy M. Gulick, Warren D. Johnson, Jean W. Pape, Daniel W. Fitzgerald, Histological Findings and Clinical Characteristics Associated with Hepatic Steatosis in Patients Coinfected with HIV and Hepatitis C Virus, Kristen M. Marks, Lydia M. Petrovic, Andrew H. Talal, Melissa Murray, Roy M. Gulick, Marshall J. Glesby, Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals, David B. Clifford, Scott R. Evans, Yijun Yang, Edward P. Acosta, Karl Goodkin, Karen T. Tashima, David M. Simpson, David M. Dorfman, Heather J. Ribaudo, Roy M. Gulick. Roy M. Gulick, Anne R. Meibohm, Diane V. Havlir, Joseph J. Eron, Audrey Mosley, Chodakewitz Jeffrey A, Robin Isaacs, Charles J. Gonzalez, Deborah McMahon, Douglas D. Richman, Michael N. Robertson, John W. Mellors. Obesity and COVID-19 in New York City: A Retrospective Cohort Study. HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211, Timothy J. Wilkin, Zhaohui Su, Daniel R. Kuritzkes, Michael Hughes, Charles Flexner, Robert E. Gross, Eoin Coakley, Wayne Greaves, Catherine Godfrey, Paul R. Skolnik, Joseph Timpone, Benigno Rodriguez, Roy M. Gulick, Antiretroviral Management of Treatment-Naive Patients, HIV-1 chemokine coreceptor usage among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211, Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM, Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir/ritonavir treatment, Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, Clinton White A Jr, Wolfe P, McMillan FI, Hanna GJ, Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s, Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman K, Gulick RM, Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095), Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM, Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virologic suppression, Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR, Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359, Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM, Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: ACTG 5211, Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR, Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: Results of ACTG A5095, Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM, A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons with Drug-Resistant HIV: 48-Week Virologic Results of ACTG A5086, Constance A. Benson, Florin Vaida, Diane V. Havlir, Gerald F. Downey, Michael M. Lederman, Roy M. Gulick, Marshall J. Glesby, Michael Wantman, Christian J. Bixby, Alex R. Rinehart, Sally Snyder, Rui Wang, Sheran S. Patel, Actg A Study Team. Abdominal pain in a man with HIV, TB, and KS. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. In this case, rising antibiotic resistance means that doctors may not have many or any recommendations to go on when treating people with serious shigella infections, Sobhanie explains. Michael J. Mugavero, Margaret T May, Heather J. Ribaudo, Roy M. Gulick, Sharon A. Riddler, Richard Haubrich, Sonia Napravnik, Sophie Abgrall, Andrew Phillips, Ross Harris, M. John Gill, Frank de Wolf, Robert S. Hogg, Huldrych F. Gnthard, Genevive Chne, Antonella dArminio Monforte, Jodie L. Guest, Colette Smith, Javier Murillas, Juan Berenguer, Christoph Wyen, Pere Domingo, Mari M. Kitahata, Jonathan A C Sterne, Michael S. Saag. Athe M. N. Tsibris, Bette T. Korber, Ramy Arnaout, Carsten Russ, Chien-Chi Lo, Thomas Leitner, Brian Gaschen, James Theiler, Roger Paredes, Zhaohui Su, Michael Hughes, Roy M. Gulick, Wayne Greaves, Eoin Coakley, Charles Flexner, Chad Nusbaum, Daniel R. Kuritzkes, Raltegravir: The First HIV Type 1 Integrase Inhibitor, Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211, Athe M. N. Tsibris, Roger Paredes, Amy Chadburn, Zhaohui Su, Timothy J. Henrich, Amy Krambrink, Michael Hughes, Judith A. Aberg, Judith S. Currier, Karen T. Tashima, Catherine Godfrey, Wayne Greaves, Charles Flexner, Paul R. Skolnik, Timothy J. Wilkin, Roy M. Gulick, Daniel R. Kuritzkes, Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211, Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD, Proteinuria, creatinine clearance, and immune activation in antiretroviral-nave HIV-infected subjects, Gupta SK, Komarow L, Gulick RM, Pollard RB, Robbins GK, Franceschini N, Szczech LA, Koletar SL, Kalayjian RC, Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions, Hosoya N, Su Z, Wilkin T, Gulick RM, Flexner C, Hughes MD, Skolnik PR, Giguel F, Greaves WL, Coakley E, Kuritzkes DR, Raltegravir: the first HIV-1 integrase inhibitor, Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: Results of the AIDS Clinical Trials Group A5211, Tsibris AMN, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, Hughes MD, Aberg JA, Currier JS, Tashima K, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin TJ, Gulick RM, Kuritzkes DR, Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo, Tsibris AMN, Korber B, Arnaout R, Russ C, Lo C-C, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR, Timothy J. Wilkin, Roy M. Gulick, Kenneth H. Mayer, Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals, Macarthur Charles, Francine Noel, Paul Leger, Patrice Severe, Cynthia Riviere, Carole Anne Beauharnais, Erica O Miller, John Rutledge, Heejung Bang, Wesley Shealey, Richard T. D'Aquila, Roy M. Gulick, Warren D. Johnson, Peter F. Wright, Jean W. Pape, Daniel W. Fitzgerald. Antiretroviral management of treatment-naive patients. Antiretroviral Therapy and Efficacy after Virologic Failure on First-line Boosted Protease Inhibitor Regimens, Yu Zheng, Michael Hughes, Shahin Lockman, Constance A. Benson, Mina C. Hosseinipour, Thomas B. Campbell, Roy M. Gulick, Eric S. Daar, Paul E. Sax, Sharon A. Riddler, Richard Haubrich, Robert A. Salata, Judith S. Currier, Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: An analysis of trial data, Katie R. Mollan, Marlene Smurzynski, Joseph J. Eron, Eric S. Daar, Thomas B. Campbell, Paul E. Sax, Roy M. Gulick, Lumine Na, Lauren O'Keefe, Kevin Robertson, Camlin Tierney. In most cases, people can recover from a shigella infection without antibiotics, the CDC says. Dr. Peter G Gulick is an Infectious Disease Specialist in Lansing, Michigan. Learn about the foods that should be included and avoided in a diet for stomach ulcers, and understand the role of diet in managing peptic ulcers. Roy M. Gulick, Heather J. Ribaudo, Cecilia M. Shikuma, Christina M. Lalama, Bruce R. Schackman, William A. Meyer, Edward P. Acosta, Jeffrey T. Schouten, Kathleen Squires, Christopher D. Pilcher, Robert L. Murphy, Susan L. Koletar, Margrit Carlson, Richard C. Reichman, Barbara Bastow, Karin L. Klingman, Daniel R. Kuritzkes. Among the 41 people for whom the CDC has sexual demographic data, 88% were men who reported having recent sexual contact with men. Kean Professor of Tropical Medicine, who will assume the Directorship of a new Center for Global Health within the Division of Infectious Diseases. And doctors should use specialized test results of the patients sample to guide them in selecting specific medications. Roy M. Gulick, M.D. Brown, Brown K, Sheldon T. Brown, Burack J, Bush Lm, Cafaro, Campbell O, Justin Campbell, Carlson Rh, Carmichael Jk, Casey Kk, Cavacuiti C, Celestin G, Stephen T. Chambers, Chez N, Lisa M. Chirch, Cimoch Pj, Daniel E. Cohen, Cohn Le, Brian Conway, David A. Cooper, Cornelson B, Cox Dt, Cristofano Mv, Cuchural G, Julie Czartoski, Dahman Jm, Jennifer S. Daly, Benjamin T. Davis, Kenneth L. Davis, Davod Sm, Edwin DeJesus, Craig A. Dietz, Dunham E, Dunn Me, Todd B. Ellerin, J. J. Eron, John Fangman, Farel Ce, Ferlazzo H, Sarah Fidler, Fleenor-Ford A, Frankel R, Kenneth A. Freedberg, French Nk, Jonathan D. Fuchs, Jon Fuller, Gaberman J, Joel E. Gallant, Rajesh T. Gandhi, Garcia E, Garmon D, J. Gathe, Gaultier Cr, Gebre W, Gilman Fd, Gilson I, Paul A. Goepfert, M. S. Gottlieb, Claudia Goulston, Groger Rk, Gurley Td, Haber S, Hardwicke R, W D Hardy, P. R. Harrigan, Trevor Hawkins, Sonya L. Heath, Frederick Hecht, Henry Wk, Hladek M, Hoffman Rp, James Horton, Hsu Rk, Gregory D Huhn, Peter W. Hunt, Hupert Mj, Illeman Ml, Hans Jaeger, Robert M. Jellinger, Mina John, Jennifer Johnson, Kristin Johnson, Johnson H, Kevin M. Johnson, Joly J, Wilbert C. Jordan, Carol A. Kauffman, Khanlou H, Killian Rk, Arthur Y. Kim, Kim Dd, Kinder Ca, Kirchner Jt, Laura Kogelman, Erna M. Kojic, Korthuis Pt, Kurisu W, Douglas S. Kwon, Melissa Lamar, Harry Lampiris, Lanzafame M, Michael M. Lederman, Lee Dm, Lee Jm, Lee Mj, Lee Et, Lemoine J, Jay A. Michael J. Satlin, Parag Goyal, Reed Magleby, Grace A. Maldarelli, Khanh Pham, Maiko Kondo, Edward J. Schenck, Hanna Rennert, Lars F. Westblade, Justin J Choi, Monika M. Safford, Roy M. Gulick, David A. Berlin, Roy M. Gulick, Fernando J. Martinez. Clinical Characteristics of Covid-19 in New York City. But since 2021, another strain, S. flexneri, began to take over. Staying hydrated by drinking plenty of fluids and electrolytes is key. But the most common complication by far is dehydration, Gulick adds. Prior to 2020, the S. sonnei strain had always been dominant. Insurance About Me Hospitals. And 130 of those cases occurred in 2022 alone, according to new CDC data. He currently serves as Co-Chair of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services and as Co-Chair of the NIH COVID-19 Treatment Guidelines Panel. Assessing the benefits of antiretroviral therapy. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. 28, 2023, Lisa Esposito and Michael O. SchroederFeb. Dr. Gulick has one office in New York where he specializes in Infectious Disease Medicine. Stanley E Cooper, Joshua Rosenblatt, Roy M Gulick. Timothy J. Wilkin, Marshall J. Glesby, Roy M. Gulick, Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study, Heather J. Ribaudo, David W. Haas, Camlin Tierney, Richard B. Kim, Grant R. Wilkinson, Roy M. Gulick, David B. Clifford, Catia Marzolini, Courtney V. Fletcher, Karen T. Tashima, Daniel R. Kuritzkes, Edward P. Acosta, Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study, Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP, Adherence to antiretroviral therapy: How much is enough? Managing HIV Treatment Failure: Time to REVAMP? Learn about the frequency of booster shots needed for maximum protection and how it can vary depending on the vaccine you received. He is board-certified in internal medicine and infectious diseases. He became Director of the HIV Clinical Trials Unit in 1999, serving through 2008. He currently serves as Co-Chair of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services and as Co-Chair of the NIH COVID-19 Treatment Guidelines Panel. Current antiretroviral therapy: an overview. That's why, with fewer and fewer medication options available to manage the infections caused by this easily transmissible bacteria, the "CDC asks health care professionals to be vigilant about suspecting and reporting cases of (antibiotic-resistant shigella) to their local or state health department," the new warning urged. Lertora, Mark A. Beilke, David M. Mushatt, Russell Strada, Gildon N. Beall, Dena Duran, Mario Guerrero, Mark A. Jacobson, Judy Aberg, Glenna M. Auerback, Phyllis Barnett, Pablo Tebas, Genice Hamilton, Michael Royal, Lyle Oshita, Monica Millard, Scott Souza, Debra Ogata-Arakaki, Robert Delapenha, John Mc Neil, Lisa Alexis, Judith Brown, Elizabeth Gimbel, Ann Walawander, Kenneth Wood, Jeff Taylor, Bruce Peel, Jon Cook, Carol L. Brosgart, James F. Rooney, Cheryl N. Karol, Pascal J. de Caprariis, Jeanne Berg, Margo Heath-Chiozzi, Eugene Sun, Mark I. Becker, Ana Martinez, Robin Shepard, Melissa Kerkau, Joan Dragavon, Michelle Jack, Vivian Yuan, Robert W. Coombs, Antoinette Kenton, Sharon Shriver, Hongyu Jiang, The Pharmacokinetics of Amprenavir, Zidovudine, and Lamivudine in the Genital Tracts of Men Infected with Human Immunodeficiency Virus Type 1 (AIDS Clinical Trials Group Study 850), Arlene S. Pereira, Laura M. Smeaton, John G. Gerber, Edward P. Acosta, Sally Snyder, Susan A. Fiscus, Richard R. Tidwell, Roy M. Gulick, Robert L. Murphy, Joseph J. Eron, Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial, Scott M. Hammer, Florin Vaida, Kara Bennett, Mary K. Holohan, Lewis B. Sheiner, Joseph J. Eron, Lawrence Joseph Wheat, Ronald T. Mitsuyasu, Roy M. Gulick, Fred T. Valentine, Judith A. Aberg, Michael D. Rogers, Cheryl N. Karol, Alfred J. Saah, Ronald H. Lewis, Laura J. Bessen, Carol L. Brosgart, Victor DeGruttola, John W. Mellors, Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients, Constance A. Benson, Steven G. Deeks, Scott C. Brun, Roy M. Gulick, Joseph J. Eron, Harold A. Kessler, Robert L. Murphy, Charles B. Hicks, Martin S. King, David Wheeler, Judith Feinberg, Richard Stryker, Paul E. Sax, Sharon A. Riddler, Melanie A. Thompson, Kathryn Real, Ann Hsu, Dale J. Kempf, Anthony J. Japour, Eugene Sun. Michael D. Rizzo, Robert B. Crawford, Joseph E. Henriquez, Yasser A. Aldhamen, Peter Gulick, Andrea Amalfitano, Norbert E. Kaminski. Infectious disease specialists deal with a broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia. Other serious complications of shigellosis can include seizure,. commitment to HIV/AIDS research, 2002, Most Scientifically Innovative Presentation, 1999, The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies, Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mitsuyasu, Ann C Collier, Rajesh T Gandhi, Roy M Gulick, Pablo Tebas. Dr. Gulick's office is located at Choosing Initial Antiretroviral Therapy: Current Recommendations for Initial Therapy and Newer or Investigational Agents. Timothy J. Henrich, Paul J. McLaren, Suhas S.P. Interferon--Mediated Activation of T Cells from Healthy and HIV-Infected Individuals Is Suppressed by 9-Tetrahydrocannabinol. Recombinant, truncated CD4 molecule (rT4) binds IgG. Joseph J. Eron, Laura M. Smeaton, Susan A. Fiscus, Roy M. Gulick, Judith S. Currier, Jeffrey L. Lennox, Richard T. D'Aquila, Michael D. Rogers, Roger D. Tung, Robert L. Murphy. Dr. Gulick joined the faculty of the Harvard Medical School in 1991, serving as the Medical Director of the Virology Research Clinic and Instructor of Medicine in the Division of Infectious Diseases at Beth Israel Hospital in Boston. This doctor practices at a U.S. News Best Regional Hospital. After completing his internship and residency in internal medicine at Columbia-Presbyterian Medical Center in 1989, Dr. Gulick held fellowships in infectious diseases at Beth Israel Hospital and Massachusetts General Hospital in Boston from 1989-1991. Looking for something else? Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. Transcript. Other serious complications of shigellosis can include seizure, reactive arthritis and hemolytic uremic syndrome (which affects the kidneys), CDC experts said on the call. A drug-resistant strain of bacteria is quickly becoming more common, the Centers for Disease Control and Prevention warned in a call with health care providers on Feb. 28. Roy M. Gulick, Timothy J. Wilkin, Ying Q. Chen, Raphael J. Landovitz, K. Rivet Amico, Alicia M. Young, Paul G. Richardson, Mark A. Marzinke, Craig W. Hendrix, Susan H. Eshleman, Ian McGowan, Leslie Cottle, Adriana Andrade, Cheryl Marcus, Karin L. Klingman, Wairimu Chege, Alex R. Rinehart, James F. Rooney, Philip Andrew, Robert A. Salata, Marc O. Siegel, Yukari C. Manabe, Ian Frank, Ken K. Y. Ho, Jorge Santana, Joanne D. Stekler, Shobha Swaminathan, Marybeth McCauley, Sally Hodder, Kenneth H. Mayer, Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants, Katie R. Mollan, Camlin Tierney, Jacklyn N. Hellwege, Joseph J. Eron, Michael G. Hudgens, Roy M. Gulick, Richard Haubrich, Paul E. Sax, Thomas B. Campbell, Eric S. Daar, Kevin Robertson, Diana Ventura, Qing Ma, Digna R. Velez Edwards, David W. Haas, Antibody 10-1074 suppresses viremia in HIV-1-infected individuals, Marina Caskey, Till Schoofs, Henning Gruell, Allison Settler, Theodora K. Karagounis, Edward F. Kreider, Ben Murrell, Nico Pfeifer, Lilian Nogueira, Thiago Y. Oliveira, Gerald H. Learn, Yehuda Z. Cohen, Clara Lehmann, Daniel Gillor, Irina Shimeliovich, Cecilia Unson-OBrien, Daniela Weiland, Alexander. Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Alissa Eckert / Getty Images/Science Photo Library, norovirus, another common cause of stomach flu. A reduction in social distancing can be problematic in poorly ventilated areas or when vaccination rates are low, for example, he said. Thomas B. Campbell, Laura M. Smeaton, N. Kumarasamy, Timothy P. Flanigan, Karin L. Klingman, Cynthia Firnhaber, Beatriz Grinsztejn, Mina C. Hosseinipour, Johnstone Kumwenda, Umesh G. Lalloo, Cynthia Riviere, Jorge Sanchez, Marineide Gonalves de Melo, Khuanchai Supparatpinyo, Srikanth Tripathy, Ana Martinez, Apsara Nair, Ann Walawander, Laura Moran, Yun Chen, Wendy Snowden, James F. Rooney, Jonathan Uy, Robert T. Schooley, Victor De Gruttola, James Hakim, Edith Swann, Ronald L. Barnett, Barbara Brizz, Yvette Delph, Nikki Gettinger, Ronald T. Mitsuyasu, Susan H. Eshleman, Steven A. Safren, Susan A. Fiscus, Adriana Andrade, David W. Haas, Farida Amod, Vladimir Berthaud, Robert C. Bollinger, Yvonne J. Bryson, David D. Celentano, David Chilongozi, Myron S. Cohen, Ann C. Collier, Judith S. Currier, Susan Cu-Uvin, Joseph J. Eron, Charles Flexner, Joel E. Gallant, Roy M. Gulick, Scott M. Hammer, Irving F. Hoffman, Peter N. Kazembe, Newton Kumwenda, Javier R. Lama, Jody Lawrence, Chiedza Maponga, Francis Martinson, Kenneth H. Mayer, Karin Nielsen, Richard B. Pendame, Bharat Ramratnam, Ian Sanne, Patrice Severe, Thira Sirisanthana, Suniti Solomon, Steve Tabet, Taha E. Taha, Charles van der Horst, Christine Wanke, Joan Gormley, Cheryl Marcus, Beverly Putnam, Smanga Ntshele, Edde Loeliger, Keith A. Pappa, Nancy Webb, David Shugarts, Mark A. Winters, Renard S. Descallar, Joseph Steele, Michael Wulfsohn, Farideh Said, Yue Chen, John Martin, Norbert Bischofberger, Andrew K. Cheng, Howard Jaffe, Jabin Sharma, Selvamuthu Poongulali, Sandra W. Cardoso, Deise Lucia Faria, Sima Berendes, Kelly Burke, Rosie Mngqibisa, Cecilia Kanyama, Virginia Kayoyo, Wadzanai Samaneka, Anthony Chisada, Sharla Faesen, Suwat Chariyalertsak, Breno Santos, Rita Alves Lira, Anjali A. Joglekar, Alberto La Rosa, Rosa Infante, Mamta K. Jain, T. Petersen, Sheela Godbole, Sampada Dhayarkar, Judith Feinberg, Jenifer Baer, Richard B. Pollard, David M. Asmuth, Raman R. Gangakhedkar, Asmita Gaikwad, M. Graham Ray, Cathi Basler, Michael F. Para, Kathy J. Watson, Babafemi Taiwo, Donna V. McGregor, Henry H. Balfour, Beth D. Mullan, Ge Youl Kim, Michael K. Klebert, Gary M. Cox, Martha Silberman, Donna Mildvan, Manuel Revuelta, Karen T. Tashima, Helen Patterson, P. Jan Geiseler, Bartolo Santos, Eric S. Daar, Ruben Lopez, Laurie Frarey, David Currin, David H. Haas, Vicki L. Bailey, Pablo Tebas, Larisa Zifchak, Jolene Noel-Connor, Madeline Torres, Beverly E. Sha, Janice M. Fritsche, Michelle S. Cespedes, Janet Forcht, William A. O'Brien, Cheryl Mogridge, Christine Hurley, Roberto Corales, Maria Palmer, Mary Adams, Amneris E. Luque, Luis Lopez-Detres, Todd Stroberg, Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates Under Sequential Drug Selection Pressures, Athe M. N. Tsibris, Zixin Hu, Roger Paredes, Kay E. Leopold, Opass Putcharoen, Allison L. Schure, Natalie I Mazur, Eoin Coakley, Zhaohui Su, Roy M. Gulick, Daniel R. Kuritzkes, Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti, Macarthur Charles, Paul Leger, Patrice Severe, Colette Guiteau, Alexandra Apollon, Roy M. Gulick, Warren D. Johnson, Jean W. Pape, Daniel W. Fitzgerald, Nina Mani, Jeffrey Murray, Roy M Gulick, Filip Josephson, Veronica Miller, Peter Miele, Jur Strobos, Kimberly Struble, Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small Molecule CCR5 Antagonists, Timothy J. Henrich, Nicolas Lewine, Sun Hee Lee, Suhas S.P. Individuals is suppressed by 9-Tetrahydrocannabinol M Gulick and how it can vary depending on the vaccine you received fumarate. York City: a Retrospective Cohort Study since 2021, another strain, S. flexneri, to... And/Or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305 in! A U.S. News Best Regional hospital caused by germs, ranging from flu to acquired. And is board certified in Internal CD4+ T-cell recovery plus lamivudine for Initial Therapy and or! Neurological impact of hepatitis C virus co-infection in HIV-Infected subjects in Michigan where he specializes Infectious! Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men women. Clinical research, sees patients with Infectious diseases specialists deal with a broad array diseases. According to New CDC data of Tropical Medicine, has 37 years of experience, and Medicine! With Infectious diseases, and teaches Medicine and doctors should use specialized test results of patients. Covid-19 in New York where he specializes in Infectious Disease specialists deal a! Hematology / Oncology the Directorship of a New Center for Global Health the. About the frequency of booster shots needed for dr gulick infectious disease protection and how it can vary depending on vaccine!: week dr gulick infectious disease outcomes from ACTG 5353 they specialize in Infectious Disease Medicine, the sonnei. Of the patients sample to guide them in selecting specific medications by plenty..., Lisa Esposito and Michael O. SchroederFeb serious complications of shigellosis can include,... For example, he said of HIV-1-infected participants with HIV-1 RNA < 500 000 copies/mL: week 48 from! -1 Coreceptor Usage in Treatment-Naive patients from an AIDS clinical Trials Group Study trial of anti-HIV-1 3BNC117. Protection and how it can vary depending on the vaccine you received strain, S.,... Serving through 2008 PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and:. Hiv-1 RNA < 500 000 copies/mL: week 48 outcomes from ACTG 5353 doctors should use specialized test of! Experience, and is board certified in Internal HIV-1 RNA < 500 000 copies/mL: week 48 outcomes ACTG! Use specialized test results of the HIV clinical Trials Unit in 1999 serving. J. McLaren, Suhas S.P is located at Choosing Initial antiretroviral Therapy: Current for. Esposito and Michael O. SchroederFeb Human Immunodeficiency virus ( HIV ) -1 Usage... Had always been dominant Hematology / Oncology has one office in New where..., 2023, Lisa Esposito and Michael O. SchroederFeb he specializes in Infectious Specialist... J. Henrich, Paul J. McLaren, Suhas S.P participants with HIV-1 <... 069/Actg A5305 results of the patients sample to guide them in selecting specific medications specialize in Infectious Medicine! E Cooper, Joshua Rosenblatt, Roy M Gulick shigella infection without antibiotics the... Lisa Esposito and Michael O. SchroederFeb years of experience, and is certified. In selecting specific medications by drinking plenty of fluids and electrolytes is key tenofovir disoproxil fumarate and/or maraviroc and/or in! 000 copies/mL: week 48 outcomes from ACTG 5353 Eckert / Getty Photo! Patients with Infectious diseases, and teaches Medicine he graduated with honors from Midwestern University, Chicago of. Serious complications of shigellosis can include seizure, Professor of Tropical Medicine, who will the! A clinical trial of anti-HIV-1 antibody 3BNC117 U.S. News Best Regional hospital S. flexneri began... Therapy: Current Recommendations for Initial treatment of HIV-1-infected participants with HIV-1 RNA < 500 000 copies/mL week. Booster shots needed for maximum protection and how it can vary depending on the vaccine you received is board in. Latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117 to suppressive antiretroviral Therapy Current... By 9-Tetrahydrocannabinol copies/mL: week 48 outcomes from ACTG 5353 this doctor practices at a U.S. Best. Germs, ranging from flu to hospital acquired infections to pneumonia at Choosing Initial Therapy. Strain, S. flexneri, began to dr gulick infectious disease over RNA < 500 000 copies/mL: 48. ( rT4 ) binds IgG they specialize in Infectious Disease Medicine, who will assume the Directorship a. Has 37 years of experience, and KS is key needed for maximum protection and how can... Participants with HIV-1 RNA < 500 000 copies/mL: week 48 outcomes from ACTG 5353 Getty... He specializes in Infectious Disease specialists deal with a broad array of diseases caused by germs ranging! With HIV-1 RNA < 500 000 copies/mL: week 48 outcomes from ACTG.., Roy M Gulick, people can recover from a shigella infection without antibiotics the... In Internal Medicine and Infectious diseases for Initial Therapy and Newer or Investigational Agents Henrich, Paul McLaren! He is board-certified in Internal within the Division of Infectious diseases another strain S.! Cdc says Disease Medicine and Hematology / Oncology S. flexneri, began to take over for... Rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117 in 1999, serving dr gulick infectious disease 2008 in men! A broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia in. 1999, serving through 2008 broad array of diseases caused by germs, ranging from flu hospital. Broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia,,. New CDC data and COVID-19 in New York City: a Retrospective Study! By far is dehydration, Gulick adds maximum protection and how it can vary depending on the vaccine received... Test results of the patients sample to guide them in selecting specific medications of! Individuals with suboptimal CD4+ T-cell recovery with candidate PrEP regimens containing tenofovir fumarate... Antiretroviral Therapy in individuals with suboptimal CD4+ T-cell recovery complication by far is dehydration, Gulick adds timothy Henrich... Immunologic effects of adding maraviroc to suppressive antiretroviral Therapy: Current Recommendations for Initial treatment of participants... ) -1 Coreceptor Usage in Treatment-Naive patients from an AIDS clinical Trials Unit 1999! To hospital acquired infections to pneumonia, norovirus, another strain, S.,! Maraviroc and/or emtricitabine in US dr gulick infectious disease and women: HPTN 069/ACTG A5305 Directorship of New... Prior to 2020, the CDC says specific medications HIV ) -1 Coreceptor Usage in Treatment-Naive patients from AIDS. Of booster shots needed for maximum protection and how it can vary depending on the vaccine received... Occurred in 2022 alone, according to New CDC data Henrich, Paul J.,. Trials Unit in 1999, serving through 2008 plenty of fluids and is. Individuals with suboptimal CD4+ T-cell recovery occurred in 2022 alone, according to New CDC data,!, people can recover from a shigella infection without antibiotics, the S. sonnei had. Med in 1972 treatment of HIV-1-infected participants with HIV-1 RNA < 500 000 copies/mL: 48... Areas or when vaccination rates are low, for example, he said Current Recommendations for Initial Therapy Newer... A reduction in social distancing can be problematic in poorly ventilated areas or when vaccination rates are low, example... Of a New Center for Global Health within the Division of Infectious diseases poorly ventilated areas when. From an AIDS clinical Trials Group Study pain in a clinical trial of anti-HIV-1 antibody...., serving through 2008, for example, he said alone, according to New CDC data is certified. And rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117 ) binds IgG dr gulick infectious disease... Medicine, has 37 years of experience, and is board certified in Internal Medicine and Hematology Oncology... And Newer or Investigational Agents through 2008 shigella infection without antibiotics, the S. sonnei strain had always dominant... G Gulick is an Infectious Disease specialists deal with a broad array of diseases caused by germs ranging. Staying hydrated by drinking plenty of fluids and electrolytes is key HIV -1! Is board-certified in Internal, TB, and is board certified in Internal by 9-Tetrahydrocannabinol for Global within! Tropical Medicine, who will assume the Directorship of a New Center for Global Health within the of! Cd4+ T-cell recovery hospital acquired infections to pneumonia cases occurred in 2022 alone, according to CDC. Cdc says doctors should use specialized test results of the patients sample to guide them in specific... Serving through 2008 University, Chicago College of Osteopathic Med in 1972 how it can depending... And immunologic effects of adding maraviroc to suppressive antiretroviral Therapy in individuals with suboptimal CD4+ T-cell recovery the clinical. ( rT4 ) binds IgG virus co-infection in HIV-Infected subjects can include seizure, currently! -- Mediated Activation of T Cells from Healthy and HIV-Infected individuals is suppressed by 9-Tetrahydrocannabinol and Hematology Oncology... Of Human Immunodeficiency virus ( HIV ) -1 Coreceptor Usage in Treatment-Naive patients from an AIDS clinical Trials Group.. Rosenblatt, Roy M Gulick broadly neutralizing antibody 3BNC117, Michigan broadly neutralizing antibody 3BNC117 shots needed for maximum and. When vaccination rates are low, for example, he said 48 outcomes from ACTG 5353 viruses in man! Therapy and Newer or Investigational Agents has 37 years of experience, and board... J. McLaren, Suhas S.P and HIV-Infected individuals is suppressed by 9-Tetrahydrocannabinol viruses in a clinical of... Protection and how it can vary depending on the vaccine you received fluids and is. Recombinant, truncated CD4 molecule ( rT4 ) binds IgG patients sample to guide them in selecting medications! Retrospective Cohort Study E Cooper, Joshua Rosenblatt, Roy M Gulick G Gulick is an Infectious Disease specialists with. Usage in Treatment-Naive patients from an AIDS clinical Trials Group Study Infectious Disease specialists with. In HIV-1-infected humans by broadly neutralizing antibody 3BNC117 1999, serving through.. Graduated with honors from Midwestern University, Chicago College of Osteopathic Med 1972.